RE:RE:RE:RE:New week, day, month, post, threadsI hear ya. There has only ever been 1 OV approved for commercial use so it's not quite like for like across the board. We have a harder path to market because it's a fairly new "idea" than others who are a little more "mainstream" therapies.
Honestly though there is so much work being done on OVs and immunotherapies so we're well placed when BP realizes the value. We're ahead of most of these companies so when one gets bought or partnered there'll be the standard stampede for OVs. Doesn't look like it's going to take long.
Have a Google man, interesting reading what's going on.